“Somatic” Tumor Genomic Profiling and Potential Germline Implications: Ethical Considerations for Children with Cancer

B.A. Seifert et al., “Germline Analysis from Tumor-germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings,” Clinical Cancer Research 22, no. 16 (2016): 4087-4094.

D.F. Clark , K.N. Maxwell et al., “Identification and Confirmation of Potentially Actionable Germline Mutations in Tumor-Only Genomic Sequencing,” Journal of Clinical Oncology Precision Oncology 3 (2019): 1–11.

B. Vogelstein et al., “Cancer Genome Landscapes,” Science 339, no. 6127 (2013): 1546-1558.

Mandelker, supra note 1; Mody, supra note 1; J. Zhang et al., “Germline Mutations in Predisposition Genes in Pediatric Cancer,” New England Journal of Medicine 373, no. 24 (2015): 2336-2346.

L.M. Johnson et al., “Integrating Next Generation Sequencing into Pediatric Oncology Practice: An Assessment of Physician Confidence and Understanding of Clinical Genomics,” Cancer 123, no. 12 (2017): 2352-2359.

S.S. Kalia et al., “Recommendations for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing, 2016 Update (ACMG SF v2.0): A Policy Statement of the American College of Medical Genetics and Genomics,” Genetics in Medicine 19, no. 2 (2017): 249-255.

DeLeonardis, supra note 1.

Meric-Bernstam, supra note 1.

DeLeonardis, supra note 1.

M. E. Robson et al., “American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility,” Journal of Clinical Oncology 33, no. 31 (2015): 3660-3667.

M. M. Li et al., “Points to Consider for Reporting of Germline Variation in Patients Undergoing Tumor Testing: A Statement of the American College of Medical Genetics and Genomics (ACMG),” Genetics in Medicine 22, no. 7 (2020): 1142-1148.

V.M. Raymond et al., “Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories,” Journal of the National Cancer Institute 108, no. 4 (2016): 1-5.

Id.

Id.

L.F. Ross et al., “Erratum: Technical Report: Ethical and Policy Issues in Genetic Testing and Screening of Children,” Genetics in Medicine 15, no. 4 (2013): 321.

B.S. Wilfond et al., “Disclosing Secondary Findings from Pediatric Sequencing to Families: Considering the ‘Benefit to Families,’” Journal of Law, Medicine & Ethics 43, no. 3 (2015): 552–558.